Simponi
Active substance: golimumab
golimumab
Centralised EU authorisationActive
Marketing holder: Janssen Cilag International NV
Verified 2026-10-09 · EMA
Analogues in other countries- Source: EMA
- Countries with the substance registered: 3
Composition
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| RU 3 |
|
| US 3 |
|
Import and control
Control by country
- Russiaprescription only
Source: GRLS (Russian state register) · record 01a120c3-a685-7552-82fa-8b5feccf8999,01a120c4-b7d8-7c86-8301-5f0c929f3173,01a120c5-a6a1-78ee-959a-54c784ccdc90;count=3 · valid from 2026-10-09 · verified 2026-10-09
- United Statesprescription only
Source: openFDA NDC · record 01a12098-d6ca-7d8d-be9e-3582cf2ce7cc,01a12098-d6d2-784c-baaf-55afea5f162c,01a1209b-4806-7c26-aa43-3ce6f97ef48d;count=3 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- EMEA/H/C/000992
- Registration status
- Active
- ATC code
- L04AB06
Sources
- product · EMA · EMEA/H/C/000992 · Verified 2026-10-09
- registration_status · EMA · EMEA/H/C/000992 · Verified 2026-10-09
- ingredients.0 · EMA · EMEA/H/C/000992 · Verified 2026-10-09